Plain-English translation of NCT06865768 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new diagnostic scan called 18F-rhPSMA-7.3 PET-mpMRI that combines two imaging technologies to help doctors better detect prostate cancer. The scan works by using a radioactive tracer that attaches to cancer cells in the prostate, making them easier to spot on the images. Researchers want to see if this new scan improves cancer detection compared to standard imaging alone.
Current prostate cancer imaging misses some cancers or creates uncertainty about which areas need biopsies. This trial aims to determine whether the new scanning method can more accurately identify where cancer is present, which could reduce unnecessary biopsies and help catch cancers that might otherwise be missed.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the radioactive tracer medication into your vein. About 50 minutes later, you will undergo a combined PET and MRI scan, which takes about 30 minutes total. Depending on what the scans show, you may then have a standard prostate biopsy using ultrasound and MRI guidance to confirm whether cancer is present. The entire process is done as part of your regular prostate cancer evaluation.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Emory University
Collaborators
National Cancer Institute (NCI), National Institutes of Health (NIH)
Enrollment target
~90 participants
Started
April 2025
Primary completion
December 2028
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David M. Schuster, MD, FACR
Emory University Hospital/Winship Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.